ICU Medical, Inc.

ICU Medical, Inc. (ICUI) Market Cap

ICU Medical, Inc. has a market capitalization of $3.25B.

Financials based on reported quarter end 2025-12-31

Price: $129.96

β–² 3.92 (3.11%)

Market Cap: 3.25B

NASDAQ Β· time unavailable

CEO: Vivek Jain

Sector: Healthcare

Industry: Medical - Instruments & Supplies

IPO Date: 1992-03-31

Website: https://www.icumed.com

ICU Medical, Inc. (ICUI) - Company Information

Market Cap: 3.25B Β· Sector: Healthcare

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

Analyst Sentiment

86%
Strong Buy

Based on 7 ratings

Analyst 1Y Forecast: $165.33

Average target (based on 3 sources)

Consensus Price Target

Low

$163

Median

$172

High

$180

Average

$172

Potential Upside: 32.0%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ ICU MEDICAL INC (ICUI) β€” Investment Overview

🧩 Business Model Overview

ICU Medical Inc. (ICUI) is a leading global provider of innovative medical devices used in infusion therapy, critical care, and oncology. The company’s primary focus is on the development, manufacture, and sale of products that help prevent medication errors and reduce the risk of catheter-related bloodstream infections. ICU Medical serves hospitals, acute care settings, and ambulatory clinics, offering a comprehensive portfolio ranging from IV sets and needle-free connectors to infusion pumps and oncology safety systems. The company has steadily expanded its operations via organic initiatives and strategic acquisitions, making it a significant player within the broader medical device ecosystem. ICUI operates an integrated business model focused on the end-to-end continuum of IV therapy: from drug preparation and delivery to clinical workflow integration and electronic documentation. The company leverages its proprietary technologies and longstanding customer relationships to build recurring revenues and create value for healthcare providers, emphasizing both patient safety and clinical efficiency.

πŸ’° Revenue Streams & Monetisation Model

ICU Medical generates its revenue from several core sources tied to the use of its medical device portfolio: - **Infusion Systems and Disposables:** The largest revenue contributor is the sale of IV sets, needle-free connectors, closed system transfer devices, and related disposables. These are high-volume, single-use products that deliver recurring revenue driven by hospital and clinic utilization. - **Infusion Consumables:** ICU Medical supplies dedicated consumables used with its infusion pumps and other hardware, establishing a 'razor-and-blade' monetisation model wherein ongoing consumable sales follow initial hardware placements. - **Infusion Hardware:** The company also offers programmable infusion pumps, multi-channel delivery systems, and associated hardware. Although the capital sales are typically non-recurring and lower margin than disposables, they drive follow-on consumables and software/service revenues. - **Oncology Safety Systems:** ICU Medical's portfolio in chemotherapy safety solutions, such as closed system transfer devices, captures a growing market need for contamination reduction in hazardous drug handling. - **Service and Software:** Revenue streams are also bolstered by maintenance contracts, software solutions (such as pump integration and documentation platforms), and technical support. Revenue sources are geographically diversified, with a significant base in North America complemented by international distribution through direct sales and partnerships.

🧠 Competitive Advantages & Market Positioning

ICU Medical possesses several durable competitive advantages: - **Product Innovation:** The company has a robust history of launching advanced safety devices, particularly needle-free connectors and closed systems, which address key infection control and medication safety mandates. - **Integrated Solutions Portfolio:** By providing a comprehensive suite of IV therapy and oncology safety solutions, ICU Medical serves as a one-stop vendor for healthcare providers, increasing switching costs and deepening customer relationships. - **Regulatory and Quality Leadership:** The company’s focus on compliance with stringent FDA and international quality standards further differentiates it as a trusted supplier, benefiting from high entry barriers for new competitors. - **Operational Scale and Manufacturing Competence:** Strategic acquisitions have enabled ICU Medical to achieve significant manufacturing scale and global supply chain control, underpinning cost competitiveness and flexibility. - **Sticky Recurring Revenues:** The heavy reliance on consumables and disposables drives stable recurring revenue streams, underpinned by multi-year contracts with hospitals and group purchasing organizations. Within the global infusion therapy market, ICU Medical is positioned as a top supplier, known for both product reliability and innovation, competing against large diversified peers as well as specialized niche players.

πŸš€ Multi-Year Growth Drivers

Several secular and internal factors are poised to drive long-term growth for ICU Medical: - **Demographics & Procedure Volumes:** The aging global population and rising incidence of chronic and acute illnesses are increasing the demand for infusion therapy and intravenous drug delivery. - **Infection Control Standards:** Heightened awareness of hospital-acquired infections and safety protocols drives adoption of advanced connectors, closed system transfer devices, and specialized disposables. - **Technological Shifts:** Increasing integration of infusion systems with electronic medical records, drug library management, and smart pump technologies creates new revenue opportunities in both hardware and software. - **Oncology Segment Expansion:** The global growth in oncology procedures and the need for safer chemotherapy drug handling benefit ICU Medical's specialized oncology safety devices. - **International Market Penetration:** Opportunity exists for further geographic expansion into emerging markets where adoption of advanced infusion technologies is accelerating. - **Acquisition-Driven Growth:** Strategic M&A has historically been a driver for ICU Medical, enabling scale, portfolio expansion, and cross-selling. - **Health System Consolidation:** The trend toward hospital consolidation and integrated care delivery models increases the value of ICU Medical’s end-to-end, standardized offerings.

⚠ Risk Factors to Monitor

Investors should be mindful of several key risks: - **Regulatory & Compliance Risk:** Medical device companies face significant regulatory scrutiny. Changes in standards, approval delays, or quality concerns could impact product availability and costs. - **Product Recall and Liability:** Device failures, product recalls, or adverse events associated with ICU Medical solutions could harm reputation and lead to legal or financial liabilities. - **Competition and Pricing Pressures:** ICU Medical operates in highly competitive markets, facing pricing pressures from larger diversified MedTech companies and potential commoditization in disposables. - **Customer Concentration:** Meaningful revenue concentration among large hospital systems and group purchasing organizations may create contract renewal risks or unfavorable pricing negotiations. - **Integration & Execution:** The company’s acquisition strategy presents integration and execution risks, particularly in realizing synergies or retaining key customers post-acquisition. - **Healthcare Policy & Reimbursement:** Shifts in hospital budgets, reimbursement rates, or healthcare policy could alter purchasing behaviors or limit funding for new technology adoption. - **Supply Chain & Raw Material Dependence:** Disruptions in global supply chains, raw material price volatility, or international trade issues can impact margins and product availability.

πŸ“Š Valuation & Market View

ICU Medical is typically valued in the context of medical device companies with high recurring revenue from disposables and consumables. The business model supports premium multiples, driven by defensible market positions, embedded customer relationships, and prospects for stable growth. Valuation frameworks often employ EBITDA, earnings, and free cash flow multiples, reflecting the importance of cash generation from recurring revenues. While large capital outlays from past acquisitions can weigh temporarily on returns, the accretive potential of scale and cross-selling benefits is a cornerstone of the long-term investment case. Relative to peers, ICU Medical could warrant a valuation premium provided evidenced success in margin expansion, product innovation, and international revenue mix diversification. However, investors should weigh historical volatility and any execution risks stemming from complex integrations. Market sentiment generally favors companies with predictable, recession-resistant healthcare exposure and visible growth drivers, although sentiment may fluctuate based on industry pricing pressures or regulatory developments.

πŸ” Investment Takeaway

ICU Medical Inc. represents an attractive pure-play in the growing field of infusion therapy and clinical safety devices. Its integrated business model, high proportion of recurring revenues, and focus on both innovation and quality position it favorably within the broader MedTech sector. Continued demographic shifts, heightened infection control standards, and technological transformation underscore compelling multi-year growth opportunities. The company’s demonstrated execution track record and accretive approach to portfolio expansion offer further support to a bullish investment thesis. However, prudent investors should closely monitor regulatory risks, competitive dynamics, potential integration challenges, and margin pressures typical in the device sector. Overall, for those seeking exposure to durable trends in healthcare delivery and patient safety, ICU Medical offers a differentiated and potentially resilient investment profile within medical devices.

⚠ AI-generated β€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"ICUI reported revenue of $540.31M for the latest fiscal year. Despite this revenue level, the company faced a net loss of $15.73M, resulting in an earnings per share (EPS) of -$0.64. The operating cash flow was positive at $60.6M, and free cash flow stood at $35.95M, indicating reasonable cash generation relative to its capital expenditures. With total assets of $4.05B and total liabilities of $1.93B, the company has a solid balance sheet, reflected in a total equity of $2.12B and a net debt of approximately $1.08B. However, market performance shows a decline, with a 1-year price change of -13.63%, and no dividends have been issued, suggesting cautious sentiment among shareholders. Analysts have set a consensus target price of $179, reflecting a potential upside from the current price of $129.4, although it remains to be seen if the company can return to profitability while improving shareholder returns."

Revenue Growth

Neutral

Solid revenue levels but growth needs to be assessed.

Profitability

Neutral

Current net loss indicates challenges in profitability.

Cash Flow Quality

Positive

Positive operating and free cash flow reflects decent cash generation.

Leverage & Balance Sheet

Good

Strong balance sheet with significant equity.

Shareholder Returns

Neutral

Negative stock performance and no dividends limit appeal.

Analyst Sentiment & Valuation

Neutral

Consensus price target suggests possible upside, but concerns linger.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

So what: ICUI’s Q4 and 2026 outlook show a business that is stabilizing operationally (record consumables quarter, modernized ERP rollout, and FDA warning letter closure), but the quarter-to-quarter and year-to-year β€œmath” is still being distorted by deconsolidation and tariffs. Management’s tone is constructiveβ€”capital environment β€œstable,” no pause in customer platform engagement, and systems growth driven by Plum Duo/Solo with modern pump/single-software connectivity. The hard part is that tariffs remain a recurring earnings limiter: $11M expense in Q4 (+$2M sequential) and an explicit 2026 assumption of ~2% of revenue, with annualization embedded in the $400M–$430M EBITDA guidance. Analyst pressure in Q&A focused on whether utilization is decelerating and whether regulatory timing could stall demand; management largely denied utilization issues and downplayed customer pause risk, but also avoided firm clearance timing, signaling lingering execution/regulatory uncertainty.

AI IconGrowth Catalysts

  • Infusion systems: double-digit LVP growth driven by accelerated implementations of Plum Duo and Plum Solo (higher ASPs; more weighted to the back half of 2026)
  • Infusion consumables: continued share gain in core infusion lines plus benefit from higher-growth oncology and niche categories
  • Regulatory/product readiness: progress on new 510(k)s for Medfusion 5000 syringe pumps, CADD ambulatory pumps, and LifeShield safety software (aims to address the primary concern from the early-2025 warning letter)
  • Order-to-cash modernization in Europe: full order-to-cash conversion on a single modern ERP instance (logistics/customer service synergies expected)

Business Development

  • Otsuka ICU Medical JV: resulted in deconsolidation of IV Solutions from the income statement (referenced as created mid-2025; lapped in May for 2026 optics)
  • Smiths Medical FDA warning letter: official closure received (broad warning letter tied to prior acquisition context)
  • OEM wind-down: ambulatory line pressured by wind down of an expiring OEM arrangement (offset to infusion systems growth)
  • OEM exit (systems): a single OEM customer decreasing for years will fully exit in 2026 (ambulatory line headwind)

AI IconFinancial Highlights

  • Q4 2025 revenue: $536M total company; +2% organic growth but -14% reported (reported impacted by IV Solutions JV deconsolidation)
  • Full-year 2025 organic growth: 5% organic for total company
  • Q4 adjusted gross margin: 40.5% (within Q3 guidance of 40%–41%)
  • Q4 tariffs: recognized $11M expense; +$2M sequential vs Q3
  • Q4 adjusted EBITDA: $98M (down 7% from $106M prior year)
  • Q4 adjusted diluted EPS: $1.91 vs $2.11 prior year (down 9%)
  • YoY adjusted EBITDA decline drivers: IV Solutions deconsolidation effect plus current-year tariffs (combined ~+$25M year-over-year impact)
  • 2026 guidance (organic revenue): low to mid-single-digit consolidated organic growth; business mix generally mid-single digits for consumables and infusion systems, and flat to down slightly for Vital Care
  • 2026 adjusted gross margin target: ~41% (assumes tariff expense ~2% of revenue; inflationary manufacturing costs and Mexican peso strengthening partly offset synergy capture)
  • 2026 operating expense target: ~25% of revenue (21% SG&A and 4% R&D)
  • 2026 adjusted EBITDA range: $400M–$430M (explicitly notes annualization of 2 items totaling ~ $25M: tariff impact + IV Solutions deconsolidation earnings)
  • 2026 adjusted EPS range: $7.75–$8.45

AI IconCapital Funding

  • Q4 balance sheet: $1.3B debt and $308M cash
  • Q4 principal repayment: $30M on Term Loan B; full-year 2025 total principal payments: $303M
  • Net leverage: ended 2025 with ~$1.0B net debt; net leverage ratio just under 2.5x
  • 2026 free cash flow: expected to improve vs 2025; prioritize debt paydown (share repurchases only after leverage target of 2x is reached, expected by beginning of 2027 based on organic cash flows)

AI IconStrategy & Ops

  • Manufacturing integration: finished integration of 2 large legacy Smiths Medical manufacturing sites; bridge inventory depletion expected toward end of 2025 (benefits begin late 2025/into 2026)
  • ERP/IT systems integration: Europe order-to-cash conversion went live this quarter; remaining regions mostly on single instance except limited legacy Smiths Medical Asia Pacific regions
  • Project completion timing: IT system integration and manufacturing plant consolidation spend peaked in Q4 and should approach completion in early 2026; expects reduced restructuring/integration spending and improved free cash flow in back half of 2026
  • Vital Care profitability actions: harvesting/ discontinuing low/negative profit SKUs; most work wraps in next few months with largest YoY revenue impacts felt in Q1 (near-term revenue assumption: flat to slightly down)

AI IconMarket Outlook

  • 2026 organic revenue growth: low to mid-single-digit consolidated
  • Consumables: guidance reiterated as unchanged; mid-single-digit assumption for medium term
  • Influsion systems: LVP growth accelerated in back half via Plum Duo/Plum Solo; ambulatory offset from expiring OEM arrangement wind-down
  • Currency: favorable to reported revenue growth in Q1 2026, closer to neutral for remainder (based on current FX; Mexican peso monitored)
  • Calendarization: quarterly growth rates higher in back half due to IV systems implementation schedule
  • Regulatory timing (Q&A context): question implied 2Q midyear; management did not commit, but stated no change in regulatory response and referenced first-pass review quality for Plum Duo filings

AI IconRisks & Headwinds

  • Tariffs: material P&L headwindβ€”$11M expense in Q4 (+$2M sequential); management assumes ~2% of 2026 revenue as tariff expense; unanticipated tariffs referenced as ~ $40M–$50M impacting the gap vs original acquisition EBITDA expectations
  • Vital Care headwind: organic growth pressure expected (flat to down slightly); reported growth impact from IV Solutions JV deconsolidation and Vital Care SKU discontinuations (largest impacts to be felt in Q1)
  • Regulatory/quality remediation overhang: warning letter closure helps, but ongoing 510(k) efforts are critical to sustain systems platform plans (risk remains 'not over until it's over')
  • Supply chain/manufacturing transition costs: IT integration, plant closures, logistics consolidations consumed cash; restructuring/integration costs peaked in Q4 and may delay free cash flow until projects complete
  • Customer demand uncertainty acknowledged: investor asked about utilization deceleration; management stated underlying demand/utilization shows no observed impact, but growth rate trends in back half were lower than prior year

Sentiment: MIXED

Note: This summary was synthesized by AI from the ICUI Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (ICUI)

Β© 2026 Stock Market Info β€” ICU Medical, Inc. (ICUI) Financial Profile